Overcoming Obstacles to Develop a Cancer Immunotherapeutic

This application notes describes the events which have lead to Dr. Brenner and MaxCyte being currently engaged in a Phase I/II clinical trial to assess the safety of escalating doses of an immunotherapeutic using MaxCyte’s cell loading system.